Posted by Michael Wonder on 24 Jan 2024
Heron Therapeutics announces FDA approval of Zynrelef indication expansion to include additional orthopaedic and soft tissue procedures
23 January 2024 - Expanded indication for Zynrelef now covers approximately 13 million procedures annually.
Heron Therapeutics today announced that the US FDA has approved its supplemental new drug application for Zynrelef (bupivacaine and meloxicam) extended release solution to expand the indication for soft tissue and orthopaedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.
